237 related articles for article (PubMed ID: 34399818)
41. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
42. Bispecific antibodies for cancer therapy: A review.
Krishnamurthy A; Jimeno A
Pharmacol Ther; 2018 May; 185():122-134. PubMed ID: 29269044
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic bispecific antibodies against intracellular tumor antigens.
Xu G; Luo Y; Wang H; Wang Y; Liu B; Wei J
Cancer Lett; 2022 Jul; 538():215699. PubMed ID: 35487312
[TBL] [Abstract][Full Text] [Related]
44. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
45. Informing Development of Bispecific Antibodies Using Physiologically Based Pharmacokinetic-Pharmacodynamic Models: Current Capabilities and Future Opportunities.
Gibbs JP; Yuraszeck T; Biesdorf C; Xu Y; Kasichayanula S
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S132-S146. PubMed ID: 33205425
[TBL] [Abstract][Full Text] [Related]
46. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
[TBL] [Abstract][Full Text] [Related]
48. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
49. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Demichelis-Gómez R; Pérez-Sámano D; Bourlon C
Curr Oncol Rep; 2019 Feb; 21(2):17. PubMed ID: 30715609
[TBL] [Abstract][Full Text] [Related]
50. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
51. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.
Sun Y; Yu X; Wang X; Yuan K; Wang G; Hu L; Zhang G; Pei W; Wang L; Sun C; Yang P
Acta Pharm Sin B; 2023 Sep; 13(9):3583-3597. PubMed ID: 37719370
[TBL] [Abstract][Full Text] [Related]
52. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.
Longhitano AP; Slavin MA; Harrison SJ; Teh BW
Blood Rev; 2021 Sep; 49():100810. PubMed ID: 33676765
[TBL] [Abstract][Full Text] [Related]
53. The potential role of Bi-specific antibodies in acute myeloid leukemia.
Yilmaz M; Ravandi F
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101218. PubMed ID: 33279174
[TBL] [Abstract][Full Text] [Related]
54. Bioassay Development for Bispecific Antibodies-Challenges and Opportunities.
Register AC; Tarighat SS; Lee HY
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069573
[TBL] [Abstract][Full Text] [Related]
55. Bispecific monoclonal antibody therapy of B-cell malignancy.
Weiner GJ; De Gast GC
Leuk Lymphoma; 1995 Jan; 16(3-4):199-207. PubMed ID: 7719227
[TBL] [Abstract][Full Text] [Related]
56. The state of the art of bispecific antibodies for treating human malignancies.
Wang S; Chen K; Lei Q; Ma P; Yuan AQ; Zhao Y; Jiang Y; Fang H; Xing S; Fang Y; Jiang N; Miao H; Zhang M; Sun S; Yu Z; Tao W; Zhu Q; Nie Y; Li N
EMBO Mol Med; 2021 Sep; 13(9):e14291. PubMed ID: 34431224
[TBL] [Abstract][Full Text] [Related]
57. Development and clinical application of bispecific antibody in the treatment of colorectal cancer.
Balibegloo M; Rezaei N
Expert Rev Clin Immunol; 2020 Jul; 16(7):689-709. PubMed ID: 32536227
[TBL] [Abstract][Full Text] [Related]
58. Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.
Grandjenette C; Dicato M; Diederich M
Curr Pharm Biotechnol; 2015; 16(8):670-83. PubMed ID: 25941884
[TBL] [Abstract][Full Text] [Related]
59. Tumor-antigen-binding bispecific antibodies for cancer treatment.
Weidle UH; Kontermann RE; Brinkmann U
Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
[TBL] [Abstract][Full Text] [Related]
60. Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy.
Acheampong DO; Adokoh CK; Ampomah P; Agyirifor DS; Dadzie I; Ackah FA; Asiamah EA
Protein Pept Lett; 2017; 24(5):456-465. PubMed ID: 28117014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
